Ameriprise’s iBio IBIO Stock Holding History

Ameriprise’s Portfolio IBIO Stock Details IBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-584,368	Closed	-$1.13M	–	4141
2025 Q4	$1.13M	Buy	584,368 +102,068	+21%	+$139K	﹤0.01%	3279
2025 Q3	$399K	Buy	+482,300	New	+$371K	﹤0.01%	3703

Other funds holding IBIO

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Ameriprise's IBIO Position: Q1 2026 in Review

Ameriprise sold out of iBio (IBIO) in Q1 2026, closing a stake of 584,368 shares — an estimated $1.13M sold.

Ameriprise first reported a position in IBIO in Q3 2025 and held it in 2 quarters. The position peaked at $1.13M in Q4 2025. 52 funds tracked by Wall St. Rank hold IBIO as of Q1 2026.

Ameriprise reported no remaining iBio position as of Q1 2026 after selling out during the quarter.
Ameriprise sold 584,368 iBio shares in Q1 2026, an estimated $1.13M.
Ameriprise first reported a position in iBio in Q3 2025 and held it in 2 quarters.
Ameriprise's iBio position peaked at $1.13M in Q4 2025.
52 funds tracked by Wall St. Rank held iBio as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.